WebinarsNew
Deep DiveNew
Explore Business Standard
WebinarsNew
Deep DiveNew
Explore Business Standard
The revenue stands at ₹4,921.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 17.25 per cent from ₹4,197.00 crore. This corresponds to a year-on-year *(YoY) growth of 54.85 per cent.
Operating Profit stands at ₹1,643.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.36 per cent from ₹1,290.00 crore. This corresponds to a year-on-year *(YoY) growth of 59.21 per cent.
PBDT stands at ₹1,326.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 27.87 per cent from ₹1,037.00 crore. This corresponds to a year-on-year *(YoY) growth of 41.21 per cent.
Profit Before Tax stands at ₹733.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 38.56 per cent from ₹529.00 crore. This corresponds to a year-on-year *(YoY) decline of 0.68 per cent.
Net Profit stands at ₹566.00 crore, reflecting a quarter-on-quarter *(QoQ) increase of 55.49 per cent from ₹364.00 crore. This represents a 3.28 per cent year-on-year *(YoY) growth for the same year.
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,921.00 | 3,178.00 | 54.85 | 13,980.00 | 11,715.00 | 19.33 |
| Expenses | 3,278.00 | 2,146.00 | 52.75 | 9,510.00 | 7,819.00 | 21.63 |
| Other Income | -12.00 | -37.00 | -67.57 | -94.00 | 23.00 | -508.70 |
| Operating Profit | 1,643.00 | 1,032.00 | 59.21 | 4,376.00 | 3,720.00 | 17.63 |
| Depreciation | 593.00 | 201.00 | 195.02 | 1,119.00 | 795.00 | 40.75 |
| Interest | 305.00 | 56.00 | 444.64 | 385.00 | 252.00 | 52.78 |
| Profit Before Tax | 733.00 | 738.00 | -0.68 | 2,872.00 | 2,673.00 | 7.44 |
| Tax | 167.00 | 190.00 | -12.11 | 844.00 | 619.00 | 36.35 |
| Net Profit | 566.00 | 548.00 | 3.28 | 2,138.00 | 1,911.00 | 11.88 |
| Category | Q1 FY26-27 | Q1 FY25-26 | Change % | FY25-26 | FY24-25 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,158.00 | 2,616.00 | 58.94 | 10,712.00 | 9,682.00 | 10.64 |
| Expenses | 2,606.00 | 1,637.00 | 59.19 | 6,728.00 | 6,131.00 | 9.74 |
| Other Income | -21.00 | -5.00 | 320.00 | 18.00 | 32.00 | -43.75 |
| Operating Profit | 3,146.00 | 2,011.00 | 56.44 | 4,002.00 | 3,583.00 | 11.69 |
| Depreciation | 575.00 | 187.00 | 207.49 | 764.00 | 760.00 | 0.53 |
| Interest | 293.00 | 45.00 | 551.11 | 341.00 | 213.00 | 60.09 |
| Profit Before Tax | 663.00 | 742.00 | -10.65 | 2,897.00 | 2,610.00 | 11.00 |
| Tax | 171.00 | 191.00 | -10.47 | 720.00 | 541.00 | 33.09 |
| Net Profit | 492.00 | 551.00 | -10.71 | 2,192.00 | 1,888.00 | 16.10 |
| Category | Q4 FY25-26 | Q3 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,197.00 | 3,303.00 | 27.07 |
| Expenses | 2,907.00 | 2,225.00 | 30.65 |
| Other Income | -17.00 | -13.00 | 30.77 |
| Operating Profit | 1,290.00 | 1,078.00 | 19.67 |
| Depreciation | 508.00 | 206.00 | 146.60 |
| Interest | 236.00 | 45.00 | 424.44 |
| Profit Before Tax | 529.00 | 814.00 | -35.01 |
| Tax | 165.00 | 179.00 | -7.82 |
| Net Profit | 364.00 | 635.00 | -42.68 |
| Category | Q1 FY26-27 | Q4 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,158.00 | 3,445.00 | 20.70 |
| Expenses | 2,606.00 | 2,283.00 | 14.15 |
| Other Income | -21.00 | -30.00 | -30.00 |
| Operating Profit | 3,146.00 | 2,522.00 | 24.74 |
| Depreciation | 575.00 | 490.00 | 17.35 |
| Interest | 293.00 | 226.00 | 29.65 |
| Profit Before Tax | 663.00 | 416.00 | 59.38 |
| Tax | 171.00 | 107.00 | 59.81 |
| Net Profit | 492.00 | 309.00 | 59.22 |
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Torrent Pharma. | 0.80% | -2.15% | 5.76% | 15.45% | 22.91% | 33.61% |
| Sun Pharma.Inds. | 0.37% | 2.07% | 7.96% | 10.44% | 25.11% | 23.66% |
| Divi's Lab. | 2.34% | 8.19% | 22.64% | 21.24% | 32.80% | 26.18% |
| Cipla | 0.43% | 4.29% | 0.92% | 10.15% | 10.89% | -2.06% |
| Zydus Lifesci. | 0.65% | 1.17% | 1.10% | 24.33% | 27.56% | 18.13% |
| Lupin | -0.29% | 0.21% | 0.77% | 2.72% | 12.92% | 29.46% |
Torrent Pharmaceuticals Ltd on Friday reported a 27 per cent decline in profit after tax to Rs 364 crore in the fourth quarter ended March 31, 2026, impacted by exceptional items outgo. The company had posted a net profit of Rs 498 crore in the corresponding period of the preceding fiscal, Torrent Pharmaceuticals said in a statement. Total revenue from operations in the fourth quarter of FY26 stood at Rs 4,197 crore as against Rs 2,959 crore in the year-ago period, it added. The company had exceptional items outgo of Rs 66 crore in the quarter, as per the regulatory filing. The board has recommended a final dividend of Rs 9 per equity share of a face value of Rs 5 each. The pharma company's India business revenue stood at Rs 2,215 crore, up 43 per cent, in the quarter, while the Brazil revenue came in at Rs 455 crore, up by 30 per cent. Revenue from the US business stood at Rs 396 crore, up 31 per cent year-on-year, Torrent Pharma said. For FY26, net profit increased to Rs 2,138
